CytomX Therapeutics
CTMX
130 hedge funds and large institutions have $245M invested in CytomX Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 47 reducing their positions, and 20 closing their positions.
1,650% more call options, than puts
Call options by funds: $70K | Put options by funds: $4K
6% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 47
2.47% less ownership
Funds ownership: 82.23% → 79.76% (-2.5%)
3% less funds holding
Funds holding: 134 → 130 (-4)
15% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 20
22% less capital invested
Capital invested by funds: $315M → $245M (-$69.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.29M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$2.85M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$2.12M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$1.97M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.61M |
| 3 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
-$3.11M |
| 4 |
First Manhattan
New York
|
-$2.28M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$1.39M |
CTMX Hedge Fund Activity: Q3 2020 in Review
130 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2020, worth a combined $245M — down 22% from $315M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CTMX and 17 opened new positions — a net loss of 3 holders — while 47 trimmed existing stakes and 44 added.
The largest buyer was BVF Inc, adding an estimated $3.29M. The largest seller was Great Point Partners, exiting entirely with an estimated $12.1M sold.
- 130 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2020, down from 134 in Q2 2020.
- Funds reported $245M of CytomX Therapeutics stock for Q3 2020, down 22% quarter-over-quarter.
- 17 funds opened new CytomX Therapeutics positions in Q3 2020 and 20 closed out, a net change of -3 holders.
- The largest CytomX Therapeutics buyer in Q3 2020 was BVF Inc, an estimated $3.29M added.
- The largest CytomX Therapeutics seller in Q3 2020 was Great Point Partners, an estimated $12.1M sold.
Based on aggregated 13F filings for Q3 2020.